Cushing Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Cushing Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Cushing Syndrome Research. Learn more about our innovative pipeline today! @ Cushing Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cushing Syndrome Pipeline Report
• In July 2025, Cortendo AB announced a study of levoconazole in participants with endogenous Cushing's Syndrome (CS) who have completed one or both parent studies or otherwise potentially qualify for this study, as defined in the eligibility criteria.
• DelveInsight's Cushing Syndrome pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cushing Syndrome treatment.
• The leading Cushing Syndrome Companies such as Relacorilant, SPI 62, CRN-04894 and others.
• Promising Cushing Syndrome Pipeline Therapies such as CRN-04894, AZD4017, SOM230, SPI 62, Relacorilant, osilodrostat, Levoketconazole, metyrapone, evoketconazole, SPI-62 and others.

Stay informed about the cutting-edge advancements in Cushing Syndrome treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Cushing Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cushing Syndrome Emerging Drugs Profile
• Relacorilant: Corcept Therapeutics
Relacorilant (CORT 125134) is a non-steroidal, selective glucocorticoid receptor II (GR II) antagonist. Upon administration, relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. Corcept is studying relacorilant in a variety of serious disorders, including Cushing's syndrome and adrenal, ovarian and pancreatic cancer. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing's syndrome and pancreatic cancer and both the United States and the European Union for the treatment of Cushing's syndrome. In December 2024, Sparrow Pharmaceuticals had submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome).

The Cushing Syndrome Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing Syndrome Treatment.
• Cushing Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing Syndrome market.

Learn more about Cushing Syndrome Drugs opportunities in our groundbreaking Cushing Syndrome research and development projects @ Cushing Syndrome Unmet Needs- https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cushing Syndrome Companies
Relacorilant, SPI 62, CRN-04894 and others.

Cushing Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cushing Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Cushing Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Cushing Syndrome Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cushing Syndrome Pipeline Report
• Coverage- Global
• Cushing Syndrome Companies- Relacorilant, SPI 62, CRN-04894 and others.
• Cushing Syndrome Pipeline Therapies- CRN-04894, AZD4017, SOM230, SPI 62, Relacorilant, osilodrostat, Levoketconazole, metyrapone, evoketconazole, SPI-62 and others.
• Cushing Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cushing Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Cushing Syndrome Pipeline on our website @ Cushing Syndrome Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Cushing Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cushing Syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Relacorilant: Corcept Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Cushing Syndrome Key Companies
21. Cushing Syndrome Key Products
22. Cushing Syndrome- Unmet Needs
23. Cushing Syndrome- Market Drivers and Barriers
24. Cushing Syndrome- Future Perspectives and Conclusion
25. Cushing Syndrome Analyst Views
26. Cushing Syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.